Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer

Not Recruiting

Trial ID: NCT01460641

Purpose

A research study of rectal cancer perfusion (how blood flows to the rectum over time). We hope to learn whether perfusion characteristics of rectal masses may be predictive of response to treatment and whether rectal perfusion characteristics can be used to follow response to treatment.

Official Title

Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer

Stanford Investigator(s)

Subhas Banerjee
Subhas Banerjee

Professor of Medicine (Gastroenterology and Hepatology)

Uri Ladabaum
Uri Ladabaum

Professor of Medicine (Gastroenterology and Hepatology)

Andrew A. Shelton, MD, FACS, FACRS
Andrew A. Shelton, MD, FACS, FACRS

Clinical Professor, Surgery - General Surgery

George A. Fisher Jr.
George A. Fisher Jr.

Colleen Haas Chair in the School of Medicine

Teri A Longacre
Teri A Longacre

Richard L. Kempson, MD, Professor in Surgical Pathology

Dominik Fleischmann
Dominik Fleischmann

Professor of Radiology (Cardiovascular Imaging)

Eligibility


Inclusion Criteria:

   - Patients with suspected or biopsy-proven, locally advanced rectal cancer will be
   eligible for enrollment.

   - Patients must be 18 years or older. Patients must not be pregnant and, if of
   child-bearing age, must take precautions not to become pregnant.

   - No life expectancy restrictions.

   - ECOG and Karnofsky Performance Status will not be employed.

   - Patients with renal failure are ineligible for this study (GFR must be > 60)

   - Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

   - Patients who have undergone prior treatment for rectal cancer are ineligible for
   enrollment.

   - No restrictions regarding use of other investigational agents.

   - Patients with severe contrast allergy are ineligible.

   - Patients who are pregnant or are trying to become pregnant are excluded from this
   study.

   - Patients who are cancer survivors or HIV-positive will not be excluded.

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Laura Gable
650-736-0798

New Trial Alerts

Receive email alerts when trials open to patients.